High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients

Our data showed high inter-laboratory variability in the assessment of HER2-low breast cancer. The findings cast doubt on whether the current test method for HER2 is robust and reliable enough to select HER2-low patients for HER2-targeted treatment in daily clinical practice.